LicianPro

Stoke Therapeutics, Inc. ·

STOK 8-K 2026-09-25

Stoke Therapeutics, Inc. (STOK) 8-K dated 2026-09-25 — accession 0001193125-26-402820.

Stoke Therapeutics, Inc. (STOK) is a biotechnology company listed on NASDAQ.

Stoke Therapeutics, Inc. filed a 8-K on 2026-09-25. Accession 0001193125-26-402820.

This 8-K covers: Director/officer change (Item 5.02). SEC EDGAR holds the official filing and its exhibits.

Latest reported STOK revenue for 2025-12-31 was $184.4M. Net income was -$6.9M. Revenue was up 404.5% from 2024-12-31 to 2025-12-31. STOK currently screens at market cap $1.88B.

Not investment advice. The STOK SEC hub lists recent forms. The stock page is the research view.

Open on SEC EDGAR

These filings as JSON? API free 100/day

Lician Pro $19.99/mo or $149/yr